ClinicalTrials.gg
Active, not recruitingNCT07548632PREDICT-1Updated Oct 27, 2026

A Clinical Study Evaluating Licaminlimab for Dry Eye Disease

A Phase 2/3 interventional study of Artificial Tear Run-in and licaminlimab in Dry Eye Disease (DED), sponsored by Oculis. Active, not recruiting at 14 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Oculis · Phase 2/3, Interventional, and Treatment

Updated Oct 27, 2026Now Active, not recruitingGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 544 studies in Dry Eye Syndromes with a site in United States — 52 open to participants now, 63 under way, 3 of them phase 3. Dry Eye Syndromes · United States.

Planned enrollment
127th of 473
160 · median 60
Started
2026
with 35 others
Phase 2/3
18 of 544
none open now
Primary completion
2026-12
later than 24 of 62 live
Registered
514th of 544
by date

Among the 544 studies in Dry Eye Syndromes with a site in United States, this one is the 127th largest by planned enrollment of the 473 interventional ones that give a count, is one of 36 that started in 2026, is one of 18 in phase 2/3, reaches primary completion later than 24 of the 62 other live ones, and was the 514th registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 208 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

52 of the 544 studies in Dry Eye Syndromes with a site in United States are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 544 studies in Dry Eye Syndromes with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the efficacy and safety of the topical ophthalmic administration of licaminlimab as compared to vehicle in participants with Dry Eye Disease and a specific genotype.

03

Conditions studied

  • Dry Eye Disease (DED)

Browse trials for

Keywords

  • licaminlimab
  • OCS-02
  • PREDICT-1
  • genotype based development
  • Eye drops
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Physician diagnosis of Dry Eye Disease in the past 6 months
  • Use of over-the-counter tears
  • Must agree to genotype testing

Key Exclusion Criteria:

- Have a history or presence of any disorder or condition that may, in the opinion of the Investigator, likely interfere with the interpretation of the study results or participant safety.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    licaminlimab

    60 mg/mL licaminlimab ophthalmic solution

    Other: Artificial Tear Run-in · Drug: licaminlimab

  • Placebo comparator
    Vehicle

    Vehicle of licaminlimab ophthalmic solution

    Other: Artificial Tear Run-in · Other: Vehicle of licaminlimab

Interventions

  • OtherArtificial Tear Run-in

    Artificial tear eye drop run-in three times daily (TID) for approximately 14 days.

  • Licaminlimab eye drops three times daily (TID) for 29 days.

  • OtherVehicle of licaminlimab

    Inert ophthalmic solution vehicle of licaminlimab, three times daily (TID) for 29 days.

06

What researchers measure

Primary outcomes

  1. Change from baseline in global ocular discomfort severity score at Day 29 in participants with DED and specific TNFR1 genotype

    Time frame: From Day 1 to Day 29

Secondary outcomes

  1. Change from baseline in global ocular discomfort severity score at Day 29 in all participants with DED (independent of genotype).

    Time frame: Day 1 to Day 29

07

Study locations

14 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Dec 2026, 8 months after the start.

Of 15 phase 2/3 interventional studies under Dry Eye Syndromes, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 18. This study's planned 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2026
First posted
Apr 23, 2026
StartActual
Apr 16, 2026
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Recruiting→Active, not recruiting
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07548632
Lead sponsor
Oculis
Responsible party
Sponsor
First posted
Apr 23, 2026
Start date
Apr 16, 2026
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Oct 27, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Licaminlimab

Start the discussion